The STatus Epilepticus Prognosis Study
NCT06590883 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2024-09-19
Summary
The goal of this study is to improve the prognosis of patients who present with Status Epilepticus (SE). In the first part of this study, the investigators aim to find better markers of good and poor outcomes of SE patients while in the ICU. The objective is to measure the levels of brain protein micro-particles that are detectable in blood samples. The investigators seek to determine whether elevated levels of micro-particles in the bloodstream in SE patients can be used to predict the eventual outcome of survivors. The goal of the second part of the study is to evaluate long-term cognitive outcomes in survivors of SE To date, there is no reliable information to inform what cognitive recovery is like for survivors of SE after ICU discharge. The objective is to use the Creyos cognitive testing platform to assess different domains of cognitive function for up to 1 year after SE onset. Patients who have pre-existing epilepsy but have not had status epilepticus will serve as patient controls for the cognitive testing portion of this study. The third part of this study will evaluate brain changes in survivors of refractory SE. To date, there are no known studies that document to what extent the anatomy of the brain changes following SE. The objective is to characterize these changes by conducting two brain research scans 6 months apart. Patients will be invited to Robart\'s Research Institute for a scan 1-3 months and 6-8 months (6 months apart) after refractory SE to measure structural and functional changes in the brain throughout the recovery process.
Conditions
- Status Epilepticus
Sponsors & Collaborators
-
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-27
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- Canada
Study Locations
More Related Trials
-
Investigating Epilepsy: Screening and Evaluation
NCT03478852 ·Status: RECRUITING
-
An Observational Study of Epilepsy: Biology and Outcomes Using Real-world Data
NCT05632978 ·Status: RECRUITING
-
Human Epilepsy Project 2: Resistant Focal Seizures Study
NCT03531008 ·Status: COMPLETED
-
Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients
NCT00236886 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
NCT02098759 ·Status: UNKNOWN ·Phase: NA
-
Assessment of Suicidality in Epilepsy - Rating Tools
NCT01085461 ·Status: COMPLETED
-
An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
NCT01607346 ·Status: TERMINATED ·Phase: PHASE4
-
Study of Predictors of Response to Anti Epilepsy in Epilepsy
NCT02883712 ·Status: TERMINATED
-
A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy
NCT06354868 ·Status: NOT_YET_RECRUITING
-
Cardiovascular Risk Reduction in Epilepsy
NCT05704439 ·Status: WITHDRAWN ·Phase: NA
-
Improving Diagnostics and Care After First Seizure
NCT06814665 ·Status: RECRUITING
-
NYU Epilepsy Self-Management Study
NCT07087821 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Anti-epileptogenic Effects of Eslicarbazepine Acetate
NCT06597084 ·Status: COMPLETED ·Phase: PHASE2
-
Late-Onset Seizures: Trial of Vascular Risk Investigation and Treatment
NCT07116330 ·Status: RECRUITING
-
PRX-00023 Therapy in Localization-Related Epilepsy
NCT01281956 ·Status: TERMINATED ·Phase: PHASE2
-
Cognitive Enhancement Intervention for Creating a Healthy L.I.F.E (Lifestyle Interventions for Epilepsy)
NCT05954182 ·Status: RECRUITING ·Phase: NA
-
Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy
NCT02655198 ·Status: UNKNOWN ·Phase: PHASE2
-
Phenotyping and Identification of Biological Markers in STXBP1 Encephalopathy
NCT06356233 ·Status: NOT_YET_RECRUITING
-
National Network for the Study of Predictors and Prevention of Sudden Unexpected Death in Drug-resistant Partial Epilepsies
NCT02572297 ·Status: COMPLETED
-
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
NCT06769659 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers
NCT01436695 ·Status: UNKNOWN
-
Managing Epilepsy Well- WebEase Project
NCT00726076 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Fluoxetine Against Seizure-induced Central Apneas
NCT02569970 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the 24/7 EEG™ SubQ System in Subjects With Uncontrolled Genetic Generalised Epilepsy Syndrome
NCT05241678 ·Status: COMPLETED
-
Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY
NCT03419000 ·Status: COMPLETED ·Phase: NA